Home / Market News / $JAZZ
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Bernstein Lowers Price Target for Jazz Pharmaceuticals

Nov 9, 2026, 2:05 PM UTC · Primary ticker $JAZZ

Bernstein has lowered its price target for Jazz Pharmaceuticals from $229 to $220, indicating a revised valuation expectation for the biopharmaceutical company. This adjustment suggests a slightly less optimistic outlook from the analyst firm, which could exert minor downward pressure on the stock.

Bernstein, a prominent financial firm, has reduced its price target for Jazz Pharmaceuticals (JAZZ) from $229 to $220. This action reflects a revised valuation expectation, likely due to updated financial models, market conditions, or company-specific news not detailed in this filing. For traders, this indicates a slightly less favorable outlook from a key analyst, which could lead to short-term negative sentiment or minor selling pressure on JAZZ shares. While not a drastic cut, it suggests that Bernstein sees less upside potential than previously, affecting investor perception of the stock's fair value. The long-term implications depend on whether other analysts follow suit or if the company releases new information that changes the narrative.

$JAZZ negative Price target cut by Bernstein
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.